Boehringer Ingelheim International Gmbh

Dr. Karl Thomae Gmbh

Boehringer Ingelheim Pharma Kg

Boehringer Ingelheim Pharma Gmbh & Co Kg

Rainer Soyka

Johannes M Weisenberger

Armin Heckel

Werner Rall

Wolfgang Eisert

Thomas Muller

Guenter Linz

Gojko Muacevic

Juergen Schnaubelt

Josef Nickl, Deceased

Christopher Meade

Ralf Anderskewitz

Rolf Schmid

Rainer Hamm

Thomas Krueger

Joerg Brandenburg

Jutta Kroeber

Rolf Bauer

Frank Himmelsbach

Birgit Jung

Uwe Joerg Ries

Peter Sieger

Marco Santagostino

Wolfgang Grell

Thomas Mueller

Adil Duran

Klaus Binder

Ludwig Gutschera

Christian Kulinna

Rainer Zimmerman

Zeno A Leuter

Andr&eacute; Steiner

Eric Haaksma

Armin Proell

Heidelore Heimroth

Norbert Birk

Günter Linz

An improved process for preparing 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-((S)-tetrahydrofuran-3-yloxy)-quinazoline and related aminocrotonyl compounds and the preparation of a suitable salt of 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-((S)-tetrahydrofuran-3-yloxy)-quinazoline for use as a pharmaceutically active substance.

Process for preparing amino crotonyl compounds

The present invention relates to a process for preparing betamimetics of formula 1, 

Process for the manufacturing of betamimetics

A process for making a compound of formula 1 or a salt thereof, wherein: wherein Ris benzyl, diphenylmethyl, or trityl, each optionally substituted at, if available, an aryl group or an aliphatic carbon atom, with a compound of formula 7 or a salt thereof, to obtain a compound of formula 5, or a salt thereof (b) reducing the nitro group of the compound of formula 5 to an amine group and mesylating this amine group and cleaving the protecting group during the reduction step or after the mesylation step to obtain the compound of formula 1.

Process for the manufacturing of pharmaceutically active 3,1-benzoxazine-2-ones

The present invention relates to bicyclic heterocycles of general formula wherein

Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them

The present invention relates to a process for preparing the compound 3-(4-piperidinyl)-2,3,4,5-tetrahydro-1,3-benzodiazepin-2(1H)-one of formula which is to be found as a structural element in CGRP-antagonists, which are particularly suitable for the oral treatment of migraine.

3-(4-piperidinyl)-2,3,4,5-tetrahydro-1,3-benzodiazepin-2(1H)-one

Pharmaceutical compositions and kits comprising:

Pharmaceutical compositions containing tiotropium salts and low-solubility salmeterol salts

The invention relates to a process suitable for large-scale industrial use for preparing compounds of general formula (I)wherein:

Process for preparing aryl-iminomethyl-carbamino acid esters

The present invention relates to new cinnamic acid salts of salmeterol, processes for the preparation thereof as well as the use thereof as pharmaceutical compositions.

Cinnamic acid salts, processes for their preparation, and their use as medicaments

The present invention relates to new substituted salicylic acid salts of salmeterol, processes for preparing them and their use

Salicylic acid salts of salmeterol

Antithrombotic phenylalkyl derivatives of the formula

Antithrombotic phenylalkyl derivatives

The invention relates to new arylsulphonamides of the formula ##STR1## (wherein A, B and R.sub.1 to R.sub.6 are as defined in claim 1, the enantiomers, the cis- and trans-isomers thereof where R.sub.4 and R.sub.5 together represent a carbon-carbon bond, and the addition salts thereof, more particularly for pharmaceutical use the physiologically acceptable addition salts thereof with inorganic or organic bases, if R.sub.6 represents a hydroxy group) which have useful pharmacological properties, particularly antithrombotic activities and thromboxane-mediating activities. Furthermore, the new compounds are also thromboxane antagonists (TRA) and thromboxane synthesis inhibitors (TSH). They also have an effect on PGE.sub.2 production.

Arylsulphonamides, pharmaceutical compositions containing these

This invention relates to pyridyl derivatives of the formula ##STR1## wherein X, Y, A, n and R.sub.3 to R.sub.8 are defined hereinbelow, the enantiomers thereof, the cis- and trans-isomers thereof, which have antithrombotic pharmaceutical activity.

Pyridyl derivatives and pharmaceutical compositions comprising these

Arylsulphonamides, pharmaceutical compositions containing these compounds

The invention relates to new arylsulphonamides of the formula ##STR1## (wherein A, B and R.sub.1 to R.sub.6 are as defined in claim 1, the enantiomers, the cis- and trans-isomers thereof where R.sub.4 and R.sub.5 together represent a carbon-carbon bond, and the addition salts thereof, more particularly for pharmaceutical use the physiologically acceptable addition salts thereof with inorganic or organic bases, if R.sub.6 represents a hydroxy group) which have useful pharmacological properties, particularly antithrombotic activities and thromboxane-mediating activities. Furthermore, the new compounds are also thromboxane antagonists (TRA) and thromboxane synthesis inhibitors (TSH) They also have an effect on PGE.sub.2 production.

Arylsulphonamides pharmaceutical compositions containing these compounds

Growing community of inventors

Biberach, Germany

Rainer Soyka